Coya Therapeutics, Inc. · NASDAQ:COYA

Coya Therapeutics — Technical Presentation (June 2023)

9 slides from Coya Therapeutics's technical presentation, Jun 7, 2023

  1. Slide 1: Unleashing the Power of Tregs

    2020 Unleashing the Power of Tregs COYA THERAPEUTICS, INC. NASDAQ: COYA | Investor Presentation May 2023 www.coyatherapeutics.com

  2. Slide 2: COYA 301: Proprietary Treg Enhancing Low-Dose IL-2 Suppresses Adaptive and Innate Immunity

    COYA 301: Proprietary Treg Enhancing Low-Dose IL-2 Suppresses Adaptive Immunity and Innate Immunity Treg Expansion/Suppressive Function Dysfunctional Tregs COYA 301 are associated with neuroinflammation promoted by activated ALS Dysfunctional Treg Functional Tregs T effector cells and activated inna

  3. Slide 3: COYA 301: Investigator-Initiated Study in Alzheimer's Disease (AD)

    COYA 301: Investigator-Initiated Study in Alzheimer’s Disease (AD) Overall Study Design • Proof-of-Concept open-label study, conducted at Houston Methodist Hospital • Population: 8 patients with mild-to-moderate AD • Treatment: 4 monthly COYA 301 cycles administered subcutaneously, followed by 2-mon

  4. Slide 4: Enhances Treg Function and Numbers in vivo (N=8)

    COYA 301 Enhances Treg Function and Numbers in vivo in AD Patients (N=8) Statistically Significant Enhancement Statistically Significant Enhancement of Treg Suppressive Function of Treg Numbers Treatment F/U Treatment F/U * ** *** *** 14 * *** * * Mean (SD) Percentage of Tregs (% of CD4) 100 12 Mean

  5. Slide 5: Significantly Lowers Plasma Proinflammatory Chemokines and Cytokines

    COYA 301 Significantly Lowers Plasma Proinflammatory Chemokines and Cytokines in AD Patients CCL11 Plasma Levels (N=8) CCL2 Plasma Levels (N=8) IL-15 Plasma Levels (N=8) Treatment F/U 600 Treatment F/U 500 Treatment F/U 14 550 ** ** * *** *** * ** *** ** ** * ** 450 12 500 Mean (SD) Level (pg/mL) Me

  6. Slide 6: Significantly Lowers Expression of Proinflammatory Cytokines

    COYA 301 Significantly Lowers Expression of Proinflammatory Cytokines in AD Patients TNFα Monocyte Expression IL-6 Monocyte Expression IL-1β Monocyte Expression Percent Change from Baseline (N=5) Mean Change from Baseline (N=5) Mean Change from Baseline (N=5) Study Day Study Day Study Day 8 30 38 60

  7. Slide 7: Improved or Halted Cognitive Decline

    COYA 301 Improved or Halted Cognitive Decline in AD Patients MMSE Score (N=8) CDR-SB Score (N=8) ADAS-Cog Score (N=8) Treatment F/U 60 8 28 ns ns ** * * 50 * 24 6 40 Mean (SD) Score Mean (SD) Score Mean (SD) Score 20 30 4 16 20 2 12 10 0 8 0 0 120 168 0 30 60 90 120 168 0 120 168 Study Day Study Day

  8. Slide 8: Case Study of Brain Imaging of AD Patient before and after COYA 301 treatment

    Case Study of Brain Imaging of AD Patient before and after COYA 301 treatment Mini-Mental State Examination (MMSE) 18 17 Better 16 16 15 Neuroinflammation (TSPO) 70-Year-Old Male Baseline MMSE: 12 15 (11C) ER-176 PET Scan at 14 MMSE score 13 Positive PIB PET Scan 13 12 13 baseline and after 4-monthl

  9. Slide 9: COYA 301 Safety & Tolerability

    COYA 301 Safety & Tolerability • Overall, COYA 301 was well tolerated. • Most common adverse events (AEs) were mild injection site reactions and mild leukopenia. • All patients completed the study. • No death or other serious AE occurred over the course of the study. 9

Coya Therapeutics — Technical Presentation (June 2023) on 6ix